Effect of vosoritide on genu varum in children with achondroplasia after 1 year in randomized placebo-controlled trials. [PDF]
White KK +6 more
europepmc +1 more source
Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management
Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort +8 more
wiley +1 more source
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of Firsekibart in Chinese Healthy Participants. [PDF]
Yong X +6 more
europepmc +1 more source
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon +12 more
wiley +1 more source
Hydroxychloroquine sulfate tablets for patients with recurrent implantation failure: a double-blind, randomized, placebo-controlled trial. [PDF]
Han DL +13 more
europepmc +1 more source
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding +6 more
wiley +1 more source
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. [PDF]
Snaith JR +3 more
europepmc +1 more source
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
F. Nevens +31 more
semanticscholar +1 more source

